panicein B₃

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: panicein B₃
• 英文别名: 3-[(E)-5-(2,5-dihydroxyphenyl)-3-methylpent-3-enyl]-6-hydroxy-2,4-dimethylbenzaldehyde
• 化学式: C₂₁H₂₄O₄
• 分子量: 340.419
• InChiKey: BCYBPYQVUROVFP-YIXHJXPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  panicein B₃ 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以4 mg的产率得到panicein G
  参考文献：
  名称：

  Sesquiterpene hydroquinones from the sponge Reniera mucosa

  摘要：

  The sponge Reniera mucosa contains eight new compounds, six of them of the panicein class (1-6) and two novel cyclohexenones renierin A (7) and renierin B (8), together with seven related known compounds (9-15). Cyclohexenones 7 and 8 might be the biosynthetic intermediates from farnesyl precursors to paniceins. The structures were elucidated by interpretation of spectral data and chemical interconversions. Four of the new compounds (2, 3, 4 and 6) showed significant in vitro cytotoxicity.

  DOI：

  10.1016/s0040-4020(01)85297-2

文献信息

• Panicein compounds, compositions and uses thereof
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US10376476B2

  公开（公告）日：2019-08-13

  The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

  本发明涉及医药和癌症治疗领域。本发明更具体地涉及一种帕尼辛或其衍生物在体外或体内降低或抑制帕特受体药物外流活性，特别是化疗药物外流活性和化疗耐药性的用途。 本公开进一步涉及此类化合物的用途，特别是制备药物组合物，以允许或提高有需要的受试者治疗癌症的效率。本发明的化合物确实可以与至少一种化疗药物联合使用，有利地用于治疗癌症、防止癌症转移和/或防止受试者癌症复发。 本发明还公开了用于预防或治疗癌症、癌症转移和/或癌症复发的方法，以及适用于制备根据本发明的组合物和/或实施本文所述方法的试剂盒。
• PANICEIN COMPOUNDS, COMPOSITIONS AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3212176B1

  公开（公告）日：2020-11-04
• PANICEIN COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20170326076A1

  公开（公告）日：2017-11-16

  The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
• [EN] PANICEIN COMPOUNDS, COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS DE PANICÉINE, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2016066594A1

  公开（公告）日：2016-05-06

  The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
• Sesquiterpene hydroquinones from the sponge Reniera mucosa
  作者：Eva Zubía、María J. Ortega、J. Luis Carballo、Javier Salvá

  DOI：10.1016/s0040-4020(01)85297-2

  日期：1994.1

  The sponge Reniera mucosa contains eight new compounds, six of them of the panicein class (1-6) and two novel cyclohexenones renierin A (7) and renierin B (8), together with seven related known compounds (9-15). Cyclohexenones 7 and 8 might be the biosynthetic intermediates from farnesyl precursors to paniceins. The structures were elucidated by interpretation of spectral data and chemical interconversions. Four of the new compounds (2, 3, 4 and 6) showed significant in vitro cytotoxicity.